Synthetic peptides derived from human antimicrobial peptide ubiquicidin accumulate at sites of infections and eradicate (multi-drug resistant) Staphylococcus aureus in mice
Synthetic peptides derived from human antimicrobial peptide ubiquicidin accumulate at sites of infections and eradicate (multi-drug resistant) Staphylococcus aureus in mice
复制标题
DOI：
10.1016/j.peptides.2006.05.022
复制
发表时间：
2006-11-01
期刊：
影响因子：
3
通讯作者：
Welling, Mick M.
中科院分区：
文献类型：
--
作者：
Brouwer, Carlo P. J. M.;Bogaards, Sylvia J. P.;Welling, Mick M.
抗菌肽（AMPS）的存在和抗菌活性已被广泛认为是先天免疫系统进化保留的一部分。基于动物模型和人类的证据，AMPS现在被定位为新型抗感染剂。目前的研究旨在评估ubiquicidin及其小的合成片段对耐甲氧西林金黄色葡萄球菌（MRSA）的潜在抗微生物活性，作为新型抗生素的高优先级靶标。通过衍生自人阳离子肽ubiquicidin（UBI 1-59）的α-螺旋或β-折叠结构域的合成肽体外杀死MRSA，允许选择AMPS用于可能的MRSA感染治疗。对于整个肽UBI 1-59和包含氨基酸31-38的合成片段，观察到最强的抗菌活性。这些小肽的可用性、化学合成机会和大小，结合它们对MRSA的强抗微生物活性，使得这些化合物成为抗微生物治疗和检测人类感染的有希望的候选物。All rights reserved.
The presence and antimicrobial activity of antimicrobial peptides (AMPS) has been widely recognized as an evolutionary preserved part of the innate immune system. Based on evidence in animal models and humans, AMPS are now positioned as novel anti-infective agents. The current study aimed to evaluate the potential antimicrobial activity of ubiquicidin and small synthetic fragments thereof towards methicillin resistant Staphylococcus aureus (MRSA), as a high priority target for novel antibiotics. In vitro killing of MRSA by synthetic peptides derived from the alpha-helix or beta-sheet domains of the human cationic peptide ubiquicidin (UBI 1-59), allowed selection of AMPS for possible treatment of MRSA infections. The strongest antibacterial activity was observed for the entire peptide UBI 1-59 and for synthetic fragments comprising amino acids 31-38. The availability, chemical synthesis opportunities, and size of these small peptides, combined with their strong antimicrobial activity towards MRSA make these compounds promising candidates for antimicrobial therapy and detection of infections in man. (c) 2006 Elsevier Inc. All rights reserved.